Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Lipid Panel Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The latest market research report on the global lipid panel testing industry has been added to our comprehensive collection of industry analysis documents. This in-depth analysis offers insights into the market's impressive expansion, anticipated trends, and key drivers shaping the future of lipid testing globally.
According to the report, the global lipid panel testing market witnessed significant growth, escalating from $10.28 billion in 2023 to an expected $11.17 billion in 2024, with a robust compound annual growth rate (CAGR) of 8.7%. This upward trajectory mirrors the heightened awareness around cardiovascular health, lifestyle changes, and the aging population's impact on healthcare systems internationally.
Looking ahead, the market is projected to reach $15.13 billion by 2028, growing at a CAGR of 7.9%. Notable growth drivers include the increasing emphasis on individualized genetic testing, the quest for early detection of cardiovascular conditions, the rise of at-home testing kits, and heightened screening in populations at high risk of heart-related diseases.
Upcoming Trends in the Lipid Panel Testing Sector
- Implementation of point-of-care testing for on-the-spot diagnostics
- Integration with electronic health records to streamline patient data management
- Advances in genetic lipid testing offering personalized health insights
- Increased availability of home-based testing kits catering to patient convenience
- Telemedicine adoption expanding the reach of healthcare services
- Educational initiatives aimed at improving lipid management awareness
The surge in cardiovascular diseases and diabetes cases stands out as a primary market catalyst. These diseases necessitate routine monitoring and effective lipid management, thus fueling the demand for advanced lipid panel testing services and products.
The escalating obesity epidemic also contributes to market growth, as it correlates with increasing rates of dyslipidemia and metabolic syndrome, positioning the lipid panel testing as a pivotal component in managing the risks associated with obesity.
In response to these healthcare challenges, leading companies are innovating and releasing progressive products. Developments such as smartphone-based diagnostic technologies are set to reshape the marketplace by emphasizing convenience, accessibility, and cutting-edge technology-adapted solutions.
The report delves into the different market segments, including various products and services like devices, kits, and professional services, along with their applications across diverse end user groups. This spans hospitals, clinics, laboratories, and other healthcare settings, reflecting the multifaceted nature of the lipid panel testing industry.
From a geographical standpoint, North America continues to dominate the market space in 2023, with Asia-Pacific poised to become the fastest-growing region. This detailed assessment covers regional dynamics and country-specific insights, providing stakeholders with a panoramic view of the market's landscape.
The provided market check-up includes analysis of the industry’s size, shares, segmentation, and various influencing factors. With a spotlight on entities earning revenue through cholesterol testing and lipoprotein analysis services, the report elucidates the market's comprehensive value within the healthcare domain.
For more information on this market, its drivers, and the opportunities it presents, you are invited to access the full lipid panel testing market research report.
A selection of companies mentioned in this report includes
- Abbott Laboratories
- Beckman Coulter Inc.
- F. Hoffmann-La Roche Ltd.
- Randox Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- PTS Diagnostics
- Quest Diagnostics Incorporated
- Alere Inc.
- EuroMedix International
- Boston Heart Diagnostics Corporation
- Eurofins Scientific SE
- Spark Diagnostics Pvt Ltd.
- Everlywell Inc.
- Horiba ABX SAS
- Siemens Healthcare GmbH
- Avanti Polar Lipids Inc.
- Nova Biomedical Corporation
- Bio-Rad Laboratories Inc.
- Cepheid Inc.
- Danaher Corporation
- DiaSorin S.p.A.
- EKF Diagnostics Holdings plc
- Grifols S.A.
- Hologic Inc.
- Illumina Inc.
- Luminex Corporation
- Meridian Bioscience Inc.
- Myriad Genetics Inc.
- Natera Inc.
- Ortho Clinical Diagnostics LLC
For more information about this report visit https://www.researchandmarkets.com/r/2wdg1y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
